Surgical teams implanted a genetically modified pig liver into a human recipient and demonstrated that the graft could perform key liver functions for an extended period before complications necessitated removal. The experiment showed proof‑of‑concept for xenotransplantation while underscoring remaining immunologic, infectious and physiologic hurdles. Although the patient ultimately died, researchers called the case important for validating gene‑editing and immunosuppression strategies that enabled cross‑species organ function. The result is likely to accelerate investment and regulatory attention in xenotransplant programs, but companies will need to address safety, long‑term graft durability and ethical oversight before broader clinical application.